Lynx Likely Received Nasdaq Warning Letter; Stock Below $1 for 30 Days | GenomeWeb

NEW YORK, Sept. 12 - Lynx Therapeutics yesterday likely received a warning letter from the Nasdaq exchange for failing to keep its share price above $1 for 30 consecutive days.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: flu susceptibility and Y chromosome variation in mice, deletion tied to epilepsy in dog breed, and more.

Sequencing is enabling the roots of some rare diseases to be determined, the Financial Times reports.

Proove Biosciences had allegedly been paying doctors to perform its opioid risk and other genetic tests, Stat News reports.

A floated budget plan could see non-military discretionary spending in the US — which includes science agency funding — fall, the New York Times reports.